Log in to save to my catalogue

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblas...

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblas...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_77ef91a4ad514631aed50eef2972200b

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

About this item

Full title

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

Publisher

England: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002287

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundTisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (ClinicalTrials.gov, NCT02435849 (ELIANA) and NCT02228096 (ENSIGN)), leading to commercialization of tisagenl...

Alternative Titles

Full title

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_77ef91a4ad514631aed50eef2972200b

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_77ef91a4ad514631aed50eef2972200b

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2020-002287

How to access this item